Enhanced MHC class i and costimulatory molecules on B16F10 cells by Ganoderma lucidum polysaccharides

Journal of Drug Targeting

Volumn 20, Issue 7, 2012, Pages 582-592

  Sun, Li Xin ^a,b   Lin, Zhi Bin ^a   Duan, Xin Suo ^b   Lu, Jie ^b   Ge, Zhi Hua ^b   Li, Xue Fei ^b   Li, Xue Jun ^a   Li, Min ^a   Xing, En Hong ^b   Song, You Xin ^b   Jia, Jing ^b   Li, Wei Dong ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b CHENGDE MEDICAL COLLEGE   (China)

Author keywords

Costimulatory molecule; Ganoderma lucidum polysaccharides; MHC class I; Tumor

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MESSENGER RNA; POLYSACCHARIDE;

ANIMAL CELL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL STIMULATION; CYTOTOXICITY; FLOW CYTOMETRY; GANODERMA LUCIDUM; IMMUNOCYTOCHEMISTRY; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ANTIGENS, CD80; ANTIGENS, CD86; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MHC CLASS I; H-2 ANTIGENS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; POLYSACCHARIDES; REISHI;

EID: 84863424818     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2012.697167     Document Type: Article

References (52)

1. Bubeník J. (2004). MHC class I down-regulation: tumour escape from immune surveillance? (review). Int J Oncol, 25, 487-491.
2. Cao LZ, Lin ZB. (2002). Regulation on maturation and function of dendritic cells by Ganoderma lucidum polysaccharides. Immunol Lett, 83, 163-169.
3. Cao LZ, Lin ZB. (2003). Regulatory effect of Ganoderma lucidumpolysaccharides on cytotoxic T-lymphocytes induced by dendritic cells in vitro. Acta Pharmacol Sin, 24, 321-326.
4. Cao QZ, Lin ZB. (2006). Ganoderma lucidum polysaccharides peptide inhibits the growth of vascular endothelial cell and the induction of VEGF in human lung cancer cell. Life Sci, 78, 1457-1463.
5. Cresswell P, Ackerman AL, Giodini A, Peaper DR, Wearsch PA. (2005). Mechanisms of MHC class I-restricted antigen processing and cross-presentation. Immunol Rev, 207, 145-157.
6. Chambers CA, Kuhns MS, Egen JG, Allison JP. (2001). CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol, 19, 565-594.
7. Chan WK, Law HK, Lin ZB, Lau YL, Chan GC. (2007). Response of human dendritic cells to different immunomodulatory polysaccharides derived from mushroom and barley. Int Immunol, 19, 891-899.
8. Costello RT, Gastaut JA, Olive D. (1999). Tumor escape from immunesurveillance. Arch Immunol Ther Exp (Warsz), 47, 83-88.
9. Das S, Ng KY, Ho PC. (2011). Design of a pectin-based microparticle formulation using zinc ions as the cross-linking agent and glutaraldehyde as the hardening agent for colonic-specific delivery of resveratrol: in vitro and in vivo evaluations. J Drug Target, 19, 446-457.
10. Frauwirth KA, Thompson CB. (2002). Activation and inhibition of lymphocytes by costimulation. J Clin Invest, 109, 295-299.
11. Gajewski TF. (2007). Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin Cancer Res, 13, 5256-5261.
12. García-Lora A, Algarra I, Collado A, Garrido F. (2003). Tumour immunology, vaccination and escape strategies. Eur J Immunogenet, 30, 177-183.
13. Geldenhuys W, Mbimba T, Bui T, Harrison K, Sutariya V. (2011). Brain-targeted delivery of paclitaxel using glutathione-coated nanoparticles for brain cancers. J Drug Target, 19, 837-845.
14. Ghosh S, Das Sarma M, Patra A, Hazra B. (2010). Anti-inflammatory and anticancer compounds isolated from Ventilago madraspatana Gaertn., Rubia cordifolia Linn. and Lantana camara Linn. J Pharm Pharmacol, 62, 1158-1166.
15. Greenfield EA, Nguyen KA, Kuchroo VK. (1998). CD28/B7 costimulation: a review. Crit Rev Immunol, 18, 389-418.
16. Gross S, Walden P. (2008). Immunosuppressive mechanisms in human tumors: why we still cannot cure cancer. Immunol Lett, 116, 7-14.
17. Hagerty DT, Evavold BD, Allen PM. (1994). Regulation of the costimulator B7, not class II major histocompatibility complex, restricts the ability of murine kidney tubule cells to stimulate CD4+ T cells. J Clin Invest, 93, 1208-1215.
18. Hsieh TC, Wu JM. (2011). Suppression of proliferation and oxidative stress by extracts of Ganoderma lucidum in the ovarian cancer cell line OVCAR-3. Int J Mol Med, 28, 1065-1069.
19. Kobayashi A, Hara H, Ohashi M, Nishimoto T, Yoshida K, Ohkohchi N, Yoshida T, Aoki K. (2007). Allogeneic MHC gene transfer enhances an effective antitumor immunity in the early period of autologous hematopoietic stem cell transplantation. Clin Cancer Res, 13, 469-7479.
20. Kohm AP, Mozaffarian A, Sanders VM. (2002). B cell receptor- and beta 2-adrenergic receptor-induced regulation of B7-2 (CD86) expression in B cells. J Immunol, 168, 6314-6322.
21. Kour K, Sangwan PL, Sangwan PL, Khan I, Koul S, Sharma SN, Kitchlu S, Bani S. (2011). Alcoholic extract of Cicer microphyllum augments Th1 immune response in normal and chronically stressed Swiss albino mice. J Pharm Pharmacol, 63, 267-277.
22. Li J, Cheng Y, Qu W, Sun Y, Wang Z, Wang H, Tian B. (2011a). Fisetin, a dietary flavonoid induces cell cycle arrest and apoptosis through activation of p53 and inhibition of NF-kappa B pathways in bladder cancer cells. Basic Clin Pharmacol Toxicol 108 84-93.
23. Li QQ, Wang G, Reed E, Huang L, Cuff CF. (2010). Evaluation of cisplatin in combination with ß-Elemene as a regimen for prostate cancer chemotherapy. Basic Clin Pharmacol Toxicol, 107, 868-876.
24. Li F, Zhang Y, Zhong Z. (2011b). Antihyperglycemic effect of Ganoderma lucidum polysaccharides on streptozotocin-induced diabetic mice. Int J Mol Sci, 12, 6135-6145.
25. Li WD, Zhang BD, Wei R, Liu JH, Lin ZB. (2008). Reversal effect of Ganoderma lucidum polysaccharide on multidrug resistance in K562/ADM cell line. Acta Pharmacol Sin, 29, 620-627.
26. Lin ZB, Zhang HN. (2004). Anti-tumor and immunoregulatory activities of Ganoderma lucidum and its possible mechanisms. Acta Pharmacol Sin, 25, 1387-1395.
27. McGowan EM, Alling N, Jackson EA, Yagoub D, Haass NK, Allen JD, Martinello-Wilks R. (2011). Evaluation of cell cycle arrest in estrogen responsive MCF-7 breast cancer cells: pitfalls of the MTS assay. PLoS ONE, 6, e20623.
28. Mey-Tal SV, Schechter C, Ehrlich R. (1997). Synthesis and turnover of beta2-microglobulin in Ad12-transformed cells defective in assembly and transport of class I major histocompatibility complex molecules. J Biol Chem, 272, 353-361.
29. Mooberry LK, Nair M, Paranjape S, McConathy WJ, Lacko AG. (2010). Receptor mediated uptake of paclitaxel from a synthetic high density lipoprotein nanocarrier. J Drug Target, 18, 53-58.
30. Nurieva R, Thomas S, Nguyen T, Martin-Orozco N, Wang Y, Kaja MK, Yu XZ, Dong C. (2006). T-cell tolerance or function is determined by combinatorial costimulatory signals. EMBO J, 25, 2623-2633.
31. Ohtsuka M, Inoko H, Kulski JK, Yoshimura S. (2008). Major histocompatibility complex (Mhc) class Ib gene duplications, organization and expression patterns in mouse strain C57BL/6. BMC Genomics, 9, 178.
32. Pamer E, Cresswell P. (1998). Mechanisms of MHC class I-restricted antigen processing. Annu Rev Immunol, 16, 323-358.
33. Pang X, Chen Z, Gao X, Liu W, Slavin M, Yao W, Yu LL. (2007). Potential of a novel polysaccharide preparation (GLPP) from Anhui-grown Ganoderma lucidum in tumor treatment and immunostimulation. J Food Sci, 72, S435-S442.
34. Restifo NP, Kawakami Y, Marincola F, Shamamian P, Taggarse A, Esquivel F, Rosenberg SA. (1993). Molecular mechanisms used by tumors to escape immune recognition: immunogenetherapy and the cell biology of major histocompatibility complex class I. J Immunother Emphasis Tumor Immunol, 14, 182-190.
35. Salomon B, Bluestone JA. (2001). Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol, 19, 225-252.
36. Sarrabayrouse G, Pich C, Moriez R, Armand-Labit V, Rochaix P, Favre G, Tilkin-Mariamé AF. (2010). Melanoma cells treated with GGTI and IFN-gamma allow murine vaccination and enhance cytotoxic response against human melanoma cells. PLoS ONE, 5, e9043.
37. Shao BM, Dai H, Xu W, Lin ZB, Gao XM. (2004). Immune receptors for polysaccharides from Ganoderma lucidum. Biochem Biophys Res Commun, 323, 133-141.
38. Song J, Lei FT, Xiong X, Haque R. (2008). Intracellular signals of T cell costimulation. Cell Mol Immunol, 5, 239-247.
39. Sun LX, Chen LH, Lin ZB, Qin Y, Zhang JQ, Yang J, Ma J, Ye T, Li WD. (2011a). Effects of Ganoderma lucidum polysaccharides on IEC-6 cell proliferation, migration and morphology of differentiation benefiting intestinal epithelium healing in vitro. J Pharm Pharmacol, 63, 1595-1603.
40. Sun LX, Lin ZB, Duan XS, Lu J, Ge ZH, Li XJ, Li M, Xing EH, Jia J, Lan TF, Li WD. (2011b). Ganoderma lucidum polysaccharides antagonize the suppression on lymphocytes induced by culture supernatants of B16F10 melanoma cells. J Pharm Pharmacol, 63, 725-735.
41. Sun LX, Lin ZB, Li XJ, Li M, Lu J, Duan XS, Ge ZH, Song YX, Xing EH, Li WD. (2011c). Promoting effects of Ganoderma lucidum polysaccharides on B16F10 cells to activate lymphocytes. Basic Clin Pharmacol Toxicol, 108, 149-154.
42. Sun LX, Lin ZB, Duan XS, Lu J, Ge ZH, Song YX, Li XJ, Li M, Xing EH, Yang N, Li WD. (2012). Stronger cytotoxicity in CTLs with granzyme B and porforin was induced by Ganoderma lucidum polysaccharides acting on B16F10 cells. Biomed Prev Nutr, 2, 113-118. DOI: 10.1016/j.bionut.2012.01.001.
43. Tham EL, Jensen PL, Mescher MF. (2001). Activation of antigen-specific T cells by artificial cell constructs having immobilized multimeric peptide-class I complexes and recombinant B7-Fc proteins. J Immunol Methods, 249, 111-119.
44. Thomas AK, Maus MV, Shalaby WS, June CH, Riley JL. (2002). A cellbased artificial antigen-presenting cell coated with anti-CD3 and CD28 antibodies enables rapid expansion and long-term growth of CD4 T lymphocytes. Clin Immunol, 105, 259-272.
45. Tilkin-Mariamé AF, Cormary C, Ferro N, Sarrabayrouse G, Lajoie- Mazenc I, Faye JC, Favre G. (2005). Geranylgeranyl transferase inhibition stimulates anti-melanoma immune response through MHC Class I and costimulatory molecule expression. FASEB J, 19, 1513-1515.
46. Wang YY, Zheng XX. (2002). A flow cytometry-based assay for quantitative analysis of cellular proliferation and cytotoxicity in vitro. J Immunol Methods, 268, 179-188.
47. You YH, Lin ZB. (2002). Protective effects of Ganoderma lucidum polysaccharides peptide on injury of macrophages induced by reactive oxygen species. Acta Pharmacol Sin, 23, 787-791.
48. Zhao H, Luo Y, Lu C, Lin N, Xiao C, Guan S, Guo DA, Liu Z, Ju D, He X, Lu A. (2010). Enteric mucosal immune response might trigger the immunomodulation activity of Ganoderma lucidum polysaccharide in mice. Planta Med, 76, 223-227.
49. Zhou ZY, Tang YP, Xiang J, Wua P, Jin HM, Wang Z, Mori M, Cai DF. (2010). Neuroprotective effects of water-soluble Ganoderma lucidum polysaccharides on cerebral ischemic injury in rats. J Ethnopharmacol, 131, 154-164.
50. Zhu XL, Chen AF, Lin ZB. (2007). Ganoderma lucidum polysaccharides enhance the function of immunological effector cells in immunosuppressed mice. J Ethnopharmacol, 111, 219-226.
51. Zhu XL, Lin ZB. (2005). Effects of Ganoderma lucidum polysaccharides on proliferation and cytotoxicity of cytokine-induced killer cells. Acta Pharmacol Sin, 26, 1130-1137.
52. Zhu XL, Lin ZB. (2006). Modulation of cytokines production, granzyme B and perforin in murine CIK cells by Ganoderma lucidum polysaccharides. Carbohydr Polymer, 63, 188-197.